ASLN - ASLAN Pharmaceuticals Limited

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
2.1000
-0.0400 (-1.87%)
At close: 3:55PM EST

2.1000 0.00 (0.00%)
After hours: 5:17PM EST

Stock chart is not supported by your current browser
Previous Close2.1400
Open2.1400
Bid2.0700 x 1000
Ask2.1300 x 1000
Day's Range2.0500 - 2.1800
52 Week Range0.3500 - 8.1800
Volume175,880
Avg. Volume1,691,362
Market Cap44.402M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-0.8550
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.67
  • ASLAN Pharmaceuticals Ltd. (ASLN) Stock Sinks As Market Gains: What You Should Know
    Zacks

    ASLAN Pharmaceuticals Ltd. (ASLN) Stock Sinks As Market Gains: What You Should Know

    ASLAN Pharmaceuticals Ltd. (ASLN) closed at $2.11 in the latest trading session, marking a -0.94% move from the prior day.

  • Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA
    Zacks

    Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA

    The FDA accepts Regeneron (REGN) and Sanofi's sBLA for Dupixent for Priority Review.

  • Has ASLAN Pharmaceuticals (ASLN) Outpaced Other Medical Stocks This Year?
    Zacks

    Has ASLAN Pharmaceuticals (ASLN) Outpaced Other Medical Stocks This Year?

    Is (ASLN) Outperforming Other Medical Stocks This Year?

  • Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
    Zacks

    Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

    Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.

  • Momenta (MNTA) Provides Pipeline Updates, Stock Rallies
    Zacks

    Momenta (MNTA) Provides Pipeline Updates, Stock Rallies

    Shares of Momenta (MNTA) rise 23.7% on pipeline updates.

  • Ultragenyx Provides Preliminary Crysvita 2019 Revenues
    Zacks

    Ultragenyx Provides Preliminary Crysvita 2019 Revenues

    Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.

  • ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why
    Zacks

    ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why

    ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Is ASLAN Pharmaceuticals (ASLN) Outperforming Other Medical Stocks This Year?
    Zacks

    Is ASLAN Pharmaceuticals (ASLN) Outperforming Other Medical Stocks This Year?

    Is (ASLN) Outperforming Other Medical Stocks This Year?

  • MarketWatch

    Aslan shares rise 6% on heavy volume

    Shares of Aslan Pharmaceuticals Ltd. gained 6% in morning trading on Wednesday on heavy volume. The Singaporean drugmaker is developing treatments for atopic dermatitis and acute myeloid leukemia, among other disease categories. The stock was one of the most active ahead of the open with more than 459,000 shares traded. Aslan's stock is down 35% year-to-date, compared to the S&P 500 , which has gained 27%.

  • Will ASLAN Continue to Surge Higher?
    Zacks

    Will ASLAN Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in ASLAN Pharmaceuticals.

  • GlobeNewswire

    ASLAN Pharmaceuticals Announces Closing of US$15 Million Public Offering of American Depositary Shares, Including Full Exercise of Underwriter’s Option to Purchase Additional ADSs

    SINGAPORE, Dec. 06, 2019 -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the.

  • MarketWatch

    Aslan Pharmaceuticals stock plunges after stock offering prices at a 52% discount

    The U.S.-listed shares of Aslan Pharmaceuticals Ltd. plunged 47% in active afternoon trading on Tuesday, after the Singapore-based biotechnology company's stock offering priced at less than half the previous session's closing price. Trading volume was 7.4 million shares, compared with the full-day average of about 2.1 million shares. The company announced in midday trading Monday that it had commenced a public offering of American Despositary Shares, but did not disclose the number of ADS to be sold or estimate a price. The stock closed Monday at $5.20, a 14-fold rise from the Nov. 13 record closing low of 37 cents, amid upbeat data from studies of its ASLAN004 and ASLAN003 products. Late Monday, the company said its public offering of about 5.1 million ADS priced at $2.50 per ADS, or 52% below Monday's closing price, for expected proceeds of about $12.8 million. All of the ADS in the offering were sold by the company. The stock has run up 71% over the past three months, but was still down 23% year to date. In comparison, the iShares Nasdaq Biotechnology ETF has run up 23% this year and the S&P 500 has climbed 23%.

  • Benzinga

    The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...

  • GlobeNewswire

    ASLAN Pharmaceuticals Announces Pricing of $12.8 Million Public Offering of American Depositary Shares

    ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has priced its previously announced underwritten public offering of 5,124,527 American Depositary Shares (“ADSs”) at a public offering price of $2.50 per ADS. Each ADS represents five ordinary shares of ASLAN. The gross proceeds to ASLAN, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $12.8 million.

  • MarketWatch

    Aslan stock pares its big gain after announcing stock offering

    Shares of Aslan Pharmaceuticals Ltd. jumped 42% on heavy volume in afternoon trading, but pared by more than half earlier gains of over 100%, after the biotechnology company took advantage of a more-than 12-fold rally in six days to sell more shares to the public. Trading volume swelled to 12.5 million shares, compared with the full-day average of about 1.6 million shares. The Singapore-based company did not provide details about the size of the public offering of American Depositary Shares (ADS). Aslan said it planned to use the proceeds from the stock offering to help fund clinical development of its ASLAN004 and ASLAN003 potential products, and for general corporate purposes. Earlier Monday, the stock had more than doubled (up as much as 114%) after Aslan provided upbeat data from a study of its atopic dermatitis treatment ASLAN004. The stock has now soared 1,132% since the company announced on Nov. 22 that preclinical data characterized ASLAN003 as a potential treatment for acute myeloid leukemia (AML). The stock has now gained 50.5% year to date, while the iShares Nasdaq Biotechnology ETF has advanced 22.7% and the S&P 500 has climbed 24.4%.

  • GlobeNewswire

    Aslan Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

    ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has commenced an underwritten public offering of its American Depositary Shares (“ADSs”) representing ordinary shares. In addition, ASLAN expects to grant the underwriter an option, exercisable at any time through and until one day before the potential closing date of this offering, to purchase up to an additional 15% of the ADSs being offered on the same terms and conditions. All ADSs to be sold in the offering will be offered by ASLAN.

  • MarketWatch

    Aslan Pharmaceuticals' stock soars on heavy volume, after rocketing nearly 9-fold the past week

    Shares of Aslan Pharmaceuticals Ltd. soared 77% in active premarket trading Monday, after the Singapore-based biopharmaceutical company revealed positive preliminary data from a proof-of-concept study of its atopic dermatitis treatment ASLAN004. The stock was the most active ahead of the open with over 346,000 shares traded. The rally comes after the stock had already rocketed nearly 9-fold from Nov. 21 through Friday, after Aslan published new preclinical data which characterized ASLAN004 as a potential treatment for acute myeloid leukemia. On Monday, the company said in a review of "unclean blinded data," the Eczema Area and Severity Index (EASI) scores of 3 patients who have completed at least one month of low dosing were reduced by 85%, 70% and 59% from baseline. "Whilst the data remains early, we had not anticipated to observe such pronounced improvements in patients enrolled into the lowest dose cohort," said Mark McHale, head of research and development at Aslan. The stock was on track to open Monday at a price that is more than 15 times the Nov. 21 closing price of 44 cents. The stock has more than doubled (up 130%) over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF has gained 16% and the S&P 500 has tacked on 7.3%.

  • GlobeNewswire

    ASLAN Pharmaceuticals Reports Positive Preliminary Data From Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis

    ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose (MAD) study of ASLAN004 for the treatment of moderate-to-severe atopic dermatitis (AD). ASLAN004 is a first-in-class fully human monoclonal antibody that binds to the IL-13 receptor α1 subunit (IL-13Rα1), blocking signalling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of AD, such as redness and itching of the skin.

  • Benzinga

    The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...

  • GlobeNewswire

    ASLAN Pharmaceuticals Announces Publication of Preclinical Data on ASLAN003 in AML in Haematologica Journal

    ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that new preclinical data characterising ASLAN003 as a potential treatment for acute myeloid leukaemia (AML) has been published in the November issue of Haematologica Journal. In the study, ASLAN003 was shown to inhibit protein synthesis and induce differentiation of AML cell lines via activation of AP-1 transcription factors. The study also confirmed that ASLAN003-meditated AP-1 activation is important for the reversal of the blocked differentiation of AML cells.

  • Benzinga

    Aslan Dips Into Penny Stock Territory After Company Flunks Late-Stage Cancer Study

    Aslan, which went public in May 2018, said its varlitinib, codenamed ASLAN001, failed in a pivotal study dubbed TreeTopp that evaluated the asset for biliary tract cancer. The multinational study evaluated 127 patients who failed first-line therapy. The median PFS was 2.83 months for varlitinib in combination with the chemotherapy drug capecitabine compared to 2.79 months for the control arm, Aslan said.

  • GlobeNewswire

    ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer

    The primary analysis of PFS yielded a hazard ratio of 0.90 in favour of varlitinib, and the ORR for varlitinib was 9.4% versus 4.8% in the control arm. - ASLAN to focus on development of ASLAN004 and other promising molecules in its portfolio. SINGAPORE, Nov. 11, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced topline data from the TreeTopp (TREatmEnT OPPortunity with varlitinib in biliary tract cancer) study in second line biliary tract cancer (BTC) patients.

  • ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Strong Buy: Rationale Behind the Upgrade
    Zacks

    ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Strong Buy: Rationale Behind the Upgrade

    ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3
    Zacks

    Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3

    Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.